Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 3/2019

01-09-2019 | Obesity

Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease

Authors: Syeda Momna Ishtiaq, Haroon Rashid, Zulfia Hussain, Muhammad Imran Arshad, Junaid Ali Khan

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 3/2019

Login to get access

Abstract

Adiponectin, a soluble adipocytokine, plays an important role in the functioning of adipose tissue and in the regulation of inflammation, particularly hepatic inflammation. The adiponectin subsequently imparts a crucial role in metabolic and hepato-inflammatory diseases. The most recent evidences indicate that lipotoxicity-induced inflammation in the liver is associated with obesity-derived alterations and remolding in adipose tissue that culminates in most prevalent liver pathology named as non-alcoholic fatty liver disease (NAFLD). A comprehensive crosstalk of adiponectin and its cognate receptors, specifically adiponectin receptor-2 in the liver mediates ameliorative effects in obesity-induced NAFLD by interaction with hepatic peroxisome proliferator-activated receptors (PPARs). Recent studies highlight the implication of molecular mediators mainly involved in the pathogenesis of obesity and obesity-driven NAFLD, however, the plausible mechanisms remain elusive. The present review aimed at collating the data regarding mechanistic approaches of adiponectin and adiponectin-activated PPARs as well as PPAR-induced adiponectin levels in attenuation of hepatic lipoinflammation. Understanding the rapidly occurring adiponectin-mediated pathophysiological outcomes might be of importance in the development of new therapies that can potentially resolve obesity and obesity-associated NAFLD.
Literature
1.
Ishtiaq SM, Khan JA, Arshad MI. Psychosocial-stress, liver regeneration and weight gain: a conspicuous pathophysiological triad. Cell Physiol Biochem. 2018;46(1):1–8.PubMed
2.
Hussain Z, Khan JA. Food intake regulation by leptin: mechanisms mediating gluconeogenesis and energy expenditure. Asian Pac J Trop Med. 2017;10(10):940–4.PubMed
3.
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–808.PubMedPubMedCentral
4.
Cowerd RB, Asmar MM, Alderman JM, Alderman EA, Garland AL, Busby WH, et al. Adiponectin lowers glucose production by increasing SOGA. Am J Pathol. 2010;177(4):1936–45.PubMedPubMedCentral
5.
Decara J, Serrano A, Pavón FJ, Rivera P, Arco R, Gavito A, et al. The adiponectin promoter activator NP-1 induces high levels of circulating TNFα and weight loss in obese (fa/fa) Zucker rats. Sci Rep. 2018;8(1):9858.PubMedPubMedCentral
6.
Xu A, Wang Y, Keshaw H, Xu LY, Lam KSL, Cooper GJS. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112(1):91–100.PubMedPubMedCentral
7.
Puhl RM, Heuer CA. The stigma of obesity: a review and update. Obesity. 2009;17(5):941–64.PubMed
8.
9.
Ghowsi M, Khazali H, Sisakhtnezhad S. Evaluation of TNF-α and IL-6 mRNAs expressions in visceral and subcutaneous adipose tissues of polycystic ovarian rats and effects of resveratrol. Iran J Basic Med Sci. 2018;21(2):165–74.PubMedPubMedCentral
10.
11.
12.
Fang H, Judd RL. Adiponectin regulation and function. Compr Physiol. 2018;8(3):1031–63.PubMed
13.
Vajro P, Paolella G, Fasano A. Microbiota and gut–liver Axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2013;56(5):461–8.PubMedPubMedCentral
14.
15.
Safi SZ, Shah H, Siok Yan GO, Qvist R. Insulin resistance provides the connection between hepatitis C virus and diabetes. Hepat Mon. 2015;15(1):e23941.PubMed
16.
Mokhtare B, Cetin M, Saglam YS. Evaluation of histopathological and Immunohistochemical effects of metformin HCl-loaded beads formulations in Streptozotocin (STZ)-nicotinamide (NA) induced diabetic rats. Pak Vet J. 2018;38(2):127–32.
17.
Shin JH, Jung JH. Non-alcoholic fatty liver disease and flavonoids: current perspectives. Clin Res Hepatol Gastroenterol. 2017;41(1):17–24.PubMed
18.
Mehmood K, Zhang H, Iqbal MK, Rehman MU. Li kun, Huang S, Shahzad M, Nabi F, Iqbal M, Li J. Tetramethylpyrazine mitigates toxicity and liver oxidative stress in Tibial dyschondroplasia chickens. Pak Vet J. 2018;38(1):76–80.
19.
Noureen S, Riaz A, Saif A, Arshad M, Qamar MF, Arshad N. Antioxidant properties of Lactobacillus brevis of horse origin and commercial lactic acid bacterial strains: a comparison. Pak Vet J. 2018;38(3):306–10.
20.
Hafez MH, Gad SB. Zinc oxide nanoparticles effect on oxidative status, brain activity, anxiety-like behavior and memory in adult and aged male rats. Pak Vet J. 2018;38(3):311–5.
21.
Akash MSH, Rehman K, Liaqat A, Numan M, Mahmood Q, Kamal S. Biochemical investigation of gender-specific association between insulin resistance and inflammatory biomarkers in types 2 diabetic patients. Biomed Pharmacother. 2018;106:285–91.PubMed
22.
Elfassy Y, Bastard J-P, McAvoy C, Fellahi S, Dupont J, Levy R. Adipokines in semen: physiopathology and effects on Spermatozoas. Int J Endocrinol. 2018;2018:1–11.
23.
Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPAR ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50(9):2094–9.PubMed
24.
Zhang L, Gao J, Tang P, Chong L, Liu Y, Liu P, et al. Nuciferine inhibits LPS-induced inflammatory response in BV2 cells by activating PPAR-γ. Int Immunopharmacol. 2018;63:9–13.PubMed
25.
Chinenov Y, Gupte R, Rogatsky I. Nuclear receptors in inflammation control: repression by GR and beyond. Mol Cell Endocrinol. 2013;380:55–64.PubMedPubMedCentral
26.
Rudraiah S, Zhang X, Wang L. Nuclear receptors as therapeutic targets in liver disease: are we there yet? Annu Rev Pharmacol Toxicol. 2016;56(1):605–26.PubMedPubMedCentral
27.
Tanaka N, Aoyama T, Kimura S, Gonzalez FJ. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther. 2017;179:142–57.PubMedPubMedCentral
28.
Trauner M, Halilbasic E. Nuclear receptors as new perspective for the Management of Liver Diseases. Gastroenterology. 2011;140(4):1120–5.PubMed
29.
Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology. 2011;53(3):1023–34.PubMed
30.
Nikravesh H, Khodayar MJ, Mahdavinia M, Mansouri E, Zeidooni L, Dehbashi F. Protective effect of gemfibrozil on hepatotoxicity induced by acetaminophen in mice: the importance of oxidative stress suppression. Adv Pharm Bull. 2018;8(2):331–9.PubMedPubMedCentral
31.
Zhu Y, Ni Y, Liu R, Hou M, Yang B, Song J, et al. PPAR-γ agonist alleviates liver and spleen pathology via inducing Treg cells during Schistosoma japonicum infection. J Immunol Res. 2018;2018:6398078.PubMedPubMedCentral
32.
Hulsmans M, Geeraert B, Arnould T, Tsatsanis C, Holvoet P. PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression. PLoS One. 2013;8(4):e62253.PubMedPubMedCentral
33.
Silva-Veiga FM, Rachid TL, de Oliveira L, Graus-Nunes F, Mandarim-de-Lacerda CA, Souza-Mello V. GW0742 (PPAR-beta agonist) attenuates hepatic endoplasmic reticulum stress by improving hepatic energy metabolism in high-fat diet fed mice. Mol Cell Endocrinol. 2018;474:227–37.PubMed
34.
Zhu P, Huang W, Li J, Ma X, Hu M, Wang Y, et al. Design, synthesis chalcone derivatives as AdipoR agonist for type 2 diabetes. Chem Biol Drug Des. 2018;92(2):1525–36.PubMed
35.
Reda E, Hassaneen S, El-Abhar HS. Novel trajectories of bromocriptine antidiabetic action: leptin-IL-6/ JAK2/p-STAT3/SOCS3, p-IR/p-AKT/GLUT4, PPAR-γ/adiponectin, Nrf2/PARP-1, and GLP-1. Front Pharmacol. 2018;9:771.PubMedPubMedCentral
36.
Parvin R, Noro E, Saito-Hakoda A, Shimada H, Suzuki S, Shimizu K, et al. Inhibitory effects of a novel PPAR-γ agonist MEKT1 on Pomc expression/ACTH secretion in AtT20 cells. PPAR Res. 2018;5346272.
37.
Hao L, Kearns J, Scott S, Wu D, Kodani SD, Morisseau C, et al. Indomethacin enhances Brown fat activity. J Pharmacol Exp Ther. 2018;365(3):467–75.PubMedPubMedCentral
38.
Khan MA, Kolb L, Skibba M, Hartmann M, Blöcher R, Proschak E, et al. A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia. 2018;61(10):2235–46.PubMedCentral
39.
Bi J, Sun K, Wu H, Chen X, Tang H, Mao J. PPARγ alleviated hepatocyte steatosis through reducing SOCS3 by inhibiting JAK2/STAT3 pathway. Biochem Biophys Res Commun. 2018;498(4):1037–44.PubMed
40.
Raso GM, Simeoli R, Russo R, Iacono A, Santoro A, Paciello O, Ferrante MC, Canani RB, Calignano A, Meli R. Effects of Sodium Butyrate and Its Synthetic Amide Derivative on Liver Inflammation and Glucose Tolerance in an Animal Model of Steatosis Induced by High Fat Diet. Alisi A, editor. PLoS ONE. 2013;8(7):e68626.
41.
42.
Pal China S, Sanyal S, Chattopadhyay N. Adiponectin signaling and its role in bone metabolism. Cytokine. 2018;112:116–31.PubMed
43.
Sayeed M, Gautam S, Verma DP, Afshan T, Kumari T, Srivastava AK, et al. A collagen domain–derived short adiponectin peptide activates APPL1 and AMPK signaling pathways and improves glucose and fatty acid metabolisms. J Biol Chem. 2018;293(35):13509–23.PubMedPubMedCentral
44.
Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439–51.PubMed
45.
Ghadge AA, Khaire AA, Kuvalekar AA. Adiponectin: a potential therapeutic target for metabolic syndrome. Cytokine Growth Factor Rev. 2018;39:151–8.PubMed
46.
Garaulet M, Hernández-Morante JJ, de Heredia FP, Tébar FJ. Adiponectin, the controversial hormone. Public Health Nutr. 2007;10(10A):1145–50.PubMed
47.
Otani T, Mizokami A, Hayashi Y, Gao J, Mori Y, Nakamura S, et al. Signaling pathway for adiponectin expression in adipocytes by osteocalcin. Cell Signal. 2015;27(3):532–44.PubMed
48.
Silva TE, Colombo G, Schiavon LL. Adiponectin: a multitasking player in the field of liver diseases. Diabetes Metab. 2014;40(2):95–107.PubMed
49.
Kaneda H, Nakajima T, Haruyama A, Shibasaki I, Hasegawa T, Sawaguchi T, et al. Association of serum concentrations of irisin and the adipokines adiponectin and leptin with epicardial fat in cardiovascular surgery patients. PLoS One. 2018;13(8):e0201499.PubMedPubMedCentral
50.
Cruz-Mejía S, Durán López HH, Navarro Meza M, Xochihua Rosas I, De la Peña S, Arroyo Helguera OE. Body mass index is associated with interleukin-1, adiponectin, oxidative stress and ioduria levels in healthy adults. Nutr Hosp. 2018;35(4):841–6.PubMed
51.
Gomaa AA, Farghaly HSM, El-Sers DA, Farrag MM, Al-Zokeim NI. Inhibition of adiposity and related metabolic disturbances by polyphenol-rich extract of Boswellia serrata gum through alteration of adipo/cytokine profiles. Inflammopharmacology. 2019;27(3):549–59.PubMed
52.
Sacerdoti D, Singh SP, Schragenheim J, Bellner L, Vanella L, Raffaele M, et al. Development of NASH in obese mice is confounded by adipose tissue increase in inflammatory NOV and oxidative stress. Int J Hepatol. 2018;3484107. https://​doi.​org/​10.​1155/​2018/​3484107.
53.
Manieri E, Herrera-Melle L, Mora A, Tomás-Loba A, Leiva-Vega L, Fernández DI, Rodríguez E, Morán L, Hernández-Cosido L, Torres JL, Seoane LM, , Cubero FJ, Marcos M, Sabio G. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J Exp Med 2019; 216(5): 1108–1119.PubMedPubMedCentral
54.
Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. Disruption of adiponectin causes insulin resistance and Neointimal formation. J Biol Chem. 2002;277(29):25863–6.PubMed
55.
Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, et al. Globular adiponectin protected Ob/Ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003;278(4):2461–8.PubMed
56.
Wei G, Yi S, Yong D, Shaozhuang L, Guangyong Z, Sanyuan H. miR-320 mediates diabetes amelioration after duodenal-jejunal bypass via targeting adipoR1. Surg Obes Relat Dis. 2018;14(7):960–71.PubMed
57.
Alzahrani B, Iseli T, Ramezani-Moghadam M, Ho V, Wankell M, Sun EJ, et al. The role of AdipoR1 and AdipoR2 in liver fibrosis. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2018;1864(3):700–8.
58.
Marra F, Bertolani C. Adipokines in liver diseases. Hepatology. 2009;50(3):957–69.PubMed
59.
Ding W, Zhang Q, Dong Y, Ding N, Huang H, Zhu X, et al. Adiponectin protects the rats liver against chronic intermittent hypoxia induced injury through AMP-activated protein kinase pathway. Sci Rep. 2016;6:34151.PubMedPubMedCentral
60.
Jung U, Choi M-S. Obesity and its metabolic complications: the role of Adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15(4):6184–223.PubMedPubMedCentral
61.
Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab. 2016;23(5):770–84.PubMedPubMedCentral
62.
Holland WL, Xia JY, Johnson JA, Sun K, Pearson MJ, Sharma AX, et al. Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis. Mol Metab. 2017;6(3):267–75.PubMedPubMedCentral
63.
Dai J, Liang K, Zhao S, Jia W, Liu Y, Wu H, et al. Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis. Proc Natl Acad Sci. 2018;115(26):E5896–905.PubMedPubMedCentral
64.
65.
Khan HA, Ahmad MZ, Khan JA, Arshad MI. Crosstalk of liver immune cells and cell death mechanisms in different murine models of liver injury and its clinical relevance. Hepatobiliary Pancreat Int. 2017;16(3):245–56.
66.
Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–83.PubMed
67.
Lim S, Quon MJ, Koh KK. Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis. 2014;233(2):721–8.PubMed
68.
Chen J, Montagner A, Tan N, Wahli W. Insights into the Role of PPARβ/δ in NAFLD. Int J Mol Sci. 2018;19(7).pii: E1893.
69.
Yu Z, Guo F, Zhang Z, Luo X, Tian J, Li H. Protective effects of glycyrrhizin on LPS and amoxicillin/potassium Clavulanate-induced liver injury in chicken. Pak Vet J. 2017;37(1):13–8.
70.
de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48:S104–12.PubMed
71.
72.
Stienstra R, Duval C, Müller M, Kersten S. PPARs, obesity, and inflammation. PPAR Res. 2007;95974.
73.
Mandrika I, Tilgase A, Petrovska R, Klovins J. Hydroxycarboxylic acid receptor ligands modulate Proinflammatory cytokine expression in human macrophages and adipocytes without affecting adipose differentiation. Biol Pharm Bull. 2018;41(10):1574–80.PubMed
74.
Salvadó L, Barroso E, Gómez-Foix AM, Palomer X, Michalik L, Wahli W, et al. PPARβ/δ prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism. Diabetologia. 2014;57(10):2126–35.PubMed
75.
Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62(3):720–33.PubMed
76.
Liss KHH, Finck BN. PPARs and nonalcoholic fatty liver disease. Biochimie. 2017;136:65–74.PubMed
77.
Magadum A, Engel F. PPARβ/δ: Linking Metabolism to Regeneration. Int J Mol Sci. 2018;19(7). pii: E2013.PubMedCentral
78.
Zhang Q, Xiang S, Liu Q, Gu T, Yao Y, Lu X. PPARγ antagonizes hypoxia-induced activation of hepatic stellate cell through cross mediating PI3K/AKT and cGMP/PKG signaling. PPAR Res. 2018;6970407.
79.
Chen W, Xi X, Zhang S, Zou C, Kuang R, Ye Z, et al. Pioglitazone protects against renal ischemia-reperfusion injury via the AMP-activated protein kinase-regulated autophagy pathway. Front Pharmacol. 2018;9:851.PubMedPubMedCentral
80.
Chen J, Liu H, Zhang X. Protective effects of rosiglitazone on hepatic ischemia reperfusion injury in rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018;43(7):732–7.PubMed
81.
Kim MJ, Park CH, Kim DH, Park MH, Park KC, Hyun MK, et al. Hepatoprotective effects of MHY3200 on high-fat, diet-induced, non-alcoholic fatty liver disease in rats. Mol Basel Switz. 2018;23(8):2057.
82.
Sikder K, Shukla SK, Patel N, Singh H, Rafiq K. High fat diet upregulates fatty acid oxidation and Ketogenesis via intervention of PPAR-γ. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2018;48(3):1317–31.
83.
Santin JR, Machado ID, Drewes CC, Kupa LD, Soares RM, Cavalcanti DM, et al. Role of an indole-thiazolidiene PPAR pan ligand on actions elicited by G-protein coupled receptor activated neutrophils. Biomed Pharmacother. 2018;105:947–55.PubMed
Metadata
Title
Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease
Authors
Syeda Momna Ishtiaq
Haroon Rashid
Zulfia Hussain
Muhammad Imran Arshad
Junaid Ali Khan
Publication date
01-09-2019
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 3/2019
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-019-09510-2

Other articles of this Issue 3/2019

Reviews in Endocrine and Metabolic Disorders 3/2019 Go to the issue

ReviewPaper

Vasopressin and Copeptin in health and disease

ReviewPaper

Calcium citrate: from biochemistry and physiology to clinical applications

ReviewPaper

Neuroendocrinological mechanisms underlying impulsive and compulsive behaviors in obesity: a narrative review of fMRI studies

ReviewPaper

Genetics, adaptation to environmental changes and archaic admixture in the pathogenesis of diabetes mellitus in Indigenous Australians

ReviewPaper

Vitamin D in physiological and pathological aging: Lesson from centenarians

ReviewPaper

Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits